Protagonist Therapeutics (NASDAQ:PTGX – Get Rating) had its price target dropped by investment analysts at JMP Securities from $31.00 to $28.00 in a research report issued on Thursday, Benzinga reports. The firm presently has a “market outperform” rating on the stock. JMP Securities’ target price indicates a potential upside of 24.89% from the stock’s current price.
Several other brokerages have also recently issued reports on PTGX. StockNews.com started coverage on shares of Protagonist Therapeutics in a report on Thursday. They set a “hold” rating on the stock. BTIG Research dropped their target price on shares of Protagonist Therapeutics to $41.00 in a report on Wednesday, November 16th. Finally, HC Wainwright increased their target price on shares of Protagonist Therapeutics from $33.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $35.50.
Protagonist Therapeutics Price Performance
PTGX stock opened at $22.42 on Thursday. The company has a market capitalization of $1.10 billion, a PE ratio of -8.37 and a beta of 2.01. Protagonist Therapeutics has a 12 month low of $6.91 and a 12 month high of $27.41. The firm’s 50-day moving average is $16.12 and its 200 day moving average is $11.22.
Institutional Trading of Protagonist Therapeutics
About Protagonist Therapeutics
Protagonist Therapeutics, Inc a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
- Get a free copy of the StockNews.com research report on Protagonist Therapeutics (PTGX)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.